Compare Johnson & Johnson (JNJ) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Morgan Stanley — how do they compare? Johnson & Johnson trades at $260.76 (market cap $626.09B), while Morgan Stanley trades at $217.34 (market cap $338.09B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.
| JNJ | MS | |
|---|---|---|
Market Cap | $626.09B | $338.09B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $228.42 |
52-Week Low | $172.78 | $144.04 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Morgan Stanley (MS) trades at $215.27, down 0.46% on the day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $50.2B in 2022 to $66.0B in 2025 and net income margin expanding to 27.59%. Recent earnings beats and the selection to lead the Anthropic IPO highlight operational strength. The consensus analyst price target is $239.58, implying potential upside.
The outlook is positive, supported by earnings momentum and strategic initiatives like AI integration in wealth management. Key risks include volatile cash flows from operations and high leverage, with debt-to-asset ratio rising to 26.1 in 2025. Analyst sentiment is bullish, with 55.77% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
